Titre:
  • 516MO Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, combined with osimertinib, as first-line therapy or after progression on osimertinib in non-small cell lung cancer (NSCLC)
Auteur:Cappuzzo, Federico; Moreno Garcia, V.; Ou, S-H.I.; Brandão, Mariana; Sanmamed, Miguel Fernández; Helissey, C.; Wislez, Marie; Call, J.A.; Grisanti, Salvatore; Johnson, Michael D L M.D.; Boni, V.; Jamme, P.; Monnet, Isabelle; Siena, S; Yan, C.; Barasa, Ben; Richard, B.; Joe, A.K.; Laus, Gianluca; Felip, Enriqueta
Informations sur la publication:Annals of oncology, 34, page (S1671)
Statut de publication:Publié, 2023-11
Sujet CREF:Cancérologie
Langue:Anglais
Identificateurs:urn:issn:0923-7534
info:doi/10.1016/j.annonc.2023.10.595
info:pii/S0923753423048019